Loomis, Sayles & Company
PDLI

Loomis, Sayles & Company’s PDL BioPharma, Inc. PDLI Stock Holding History

Loomis, Sayles & Company’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,526
Closed -$62K – 1208
2015
Q4 		$62K Hold
17,526
– – ﹤0.01% 731
2015
Q3 		$88K Buy
+17,526
New +$100K ﹤0.01% 762

Other funds holding PDLI

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Gotham Asset Management
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Loomis, Sayles & Company's PDLI Position: Q1 2016 in Review

Loomis, Sayles & Company sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 17,526 shares — an estimated $62K sold.

Loomis, Sayles & Company first reported a position in PDLI in Q3 2015 and held it in 2 quarters. The position peaked at $88K in Q3 2015. 196 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

  • Loomis, Sayles & Company reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Loomis, Sayles & Company sold 17,526 PDL BioPharma, Inc. shares in Q1 2016, an estimated $62K.
  • Loomis, Sayles & Company first reported a position in PDL BioPharma, Inc. in Q3 2015 and held it in 2 quarters.
  • Loomis, Sayles & Company's PDL BioPharma, Inc. position peaked at $88K in Q3 2015.
  • 196 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Loomis, Sayles & Company's 13F filing for Q1 2016, filed 13 May 2016.